Rituximab, gemcitabine and oxaliplatin: An effective regimen in patients with refractory and relapsing mantle cell lymphoma

References

• Evans L S, Hancock B W. Non-Hodgkin lymphoma. Lancet 2003; 362: 139–146
   PubMed Web of Science ®Google Scholar
• Witzig T E. Current treatment approaches for mantle-cell lymphoma. J Clin Oncol 2005; 23: 6409–6414
   PubMed Web of Science ®Google Scholar
• Romaguera J, Fayad L, Rodriguez M, Hagemeister F B, Pro B, McLaughlin P, et al. Blastoid mantle cell lymphoma (MCL): 5-yr failure-free survival (FFS) rate of 50%, without failures after 2.5 years following treatment with rituximab (R)-hyperCVAD alternating with R-methotrexate/cytarabine (M/A). Blood (Suppl.) 2006; 108: 2749
   Google Scholar
• Kiss T L, Mollee P, Lazarus H M, Lipton J H. Stem cell transplantation for mantle cell lymphoma: if, when and how?. Bone Marrow Transplant 2005; 36: 655–661
   PubMed Web of Science ®Google Scholar
• Dumontet C, Morschhauser F, Solal-Celigny P, Bouafia F, Bourgeois E, Thieblemont C, et al. Gemcitabine as a single agent in the treatment of relapsed or refractory low-grade non-Hodgkin's lymphoma. Br J Haematol 2001; 113: 772–778
   PubMed Web of Science ®Google Scholar
• Savage D G, Rule S A, Tighe M, Garrett T J, Oster M W, Lee R T, et al. Gemcitabine for relapsed or resistant lymphoma. Ann Oncol 2000; 11: 595–597
   PubMed Web of Science ®Google Scholar
• Fossa A, Santoro A, Hiddemann W, Truemper L, Niederle N, Buksmaui S, et al. Gemcitabine as a single agent in the treatment of relapsed or refractory aggressive non-Hodgkin's lymphoma. J Clin Oncol 1999; 17: 3786–3792
   PubMed Web of Science ®Google Scholar
• Bernell P, Ohm L. Promising activity of gemcitabine in refractory high-grade non-Hodgkin's lymphoma. Br J Haematol 1998; 101: 203–204
   PubMed Web of Science ®Google Scholar
• Germann N, Brienza S, Rotarski M, Emile J F, Di Palma M, Musset M, et al. Preliminary results on the activity of oxaliplatin (L-OHP) in refractory/recurrent non-Hodgkin's lymphoma patients. Ann Oncol 1999; 10: 351–354
   PubMed Web of Science ®Google Scholar
• Berinstein N L, Mangel J. Integrating monoclonal antibodies into the management of mantle cell lymphoma. Semin Oncol 2004; 31(Suppl 2)2–6
   PubMed Web of Science ®Google Scholar
• Sampol A, Rodriguez J, Galmes B, Gutierrez A, Besalduch J. Gemcitabine and oxaliplatinum: an effective regimen in a patient with progressive refractory mantle cell lymphoma. Leuk Lymphoma 2004; 45: 1289–1291
   PubMed Web of Science ®Google Scholar
• A predictive model for aggressive non-Hodgkin's lymphoma. The International Non-Hodgkin's Lymphoma Prognostic Factors project. N Engl J Med 1993; 329: 987–994
   PubMed Web of Science ®Google Scholar
• Rodriguez J, Cabanillas F, McLaughlin P, Swan F, Rodriguez M, Hagemeister F, et al. A proposal for a simple staging system for intermediate grade lymphoma and immunoblastic lymphoma based on the ‘tumor score’. Ann Oncol 1992; 3: 711–717
   PubMed Web of Science ®Google Scholar
• Cheson B D, Horning S J, Coiffier B, Shipp M A, Fisher R I, Connors J M, et al. Report of an international workshop to standardize response criteria for non-Hodgkin's lymphomas. NCI Sponsored International Working Group. J Clin Oncol 1999; 17: 1244
   PubMed Web of Science ®Google Scholar
• Kaplan E, Meier P. Nonparametric estimation from incomplete observations. J Am Stat Assoc 1958; 53: 457–481
   Web of Science ®Google Scholar
• Peto R, Pike M C, Armitage P, Breslow N E, Cox D R, Howard S V, et al. Design and analysis of randomized clinical trials requiring prolonged observation of each patient. II. Analysis and examples. Br J Cancer 1977; 35: 1–39
   PubMed Web of Science ®Google Scholar
• Cox D R. Regression models and life-tables. J R Stat Soc 1972; 34: 187
   Google Scholar
• Howard O M, Gribben J G, Neuberg D S, Grossbard M, Poor C, Janicek M J, et al. Rituximab and CHOP induction therapy for newly diagnosed mantle-cell lymphoma: molecular complete responses are not predictive of progression-free survival. J Clin Oncol 2002; 20: 1288–1294
   PubMed Web of Science ®Google Scholar
• Romaguera J E, Fayad L, Rodriguez M A, Broglio K R, Hagemeister F B, Pro B, et al. High rate of durable remissions after treatment of newly diagnosed aggressive mantle-cell lymphoma with rituximab plus hyper-CVAD alternating with rituximab plus high-dose methotrexate and cytarabine. J Clin Oncol 2005; 23: 7013–7023
   PubMed Web of Science ®Google Scholar
• Mavroudis D, Pappas P, Kouroussis C, Kakolyris S, Agelaki S, Kalbakis K, et al. A dose-escalation and pharmacokinetic study of gemcitabine and oxaliplatin in patients with advanced solid tumors. Ann Oncol 2003; 14: 304–312
   PubMed Web of Science ®Google Scholar
• Lorusso P M. Oxaliplatin in tumors other than colorectal cancer. Oncology (Williston Park) 2000; 14(Suppl 11)33–37
   PubMed Web of Science ®Google Scholar
• Corazzelli G, Russo F, Capobianco G, Marcacci G, Della Cioppa P, Pinto A. Gemcitabine, ifosfamide, oxaliplatin and rituximab (R-GIFOX), a new effective cytoreductive/mobilizing salvage regimen for relapsed and refractory aggressive non-Hodgkin's lymphoma: results of a pilot study. Ann Oncol 2006; 17(Suppl 4)iv18–iv24
   PubMed Web of Science ®Google Scholar
• Oki Y, McLaughlin P, Pro B, Hagemeister F B, Bleyer A, Loyer E, et al. Phase II study of oxaliplatin in patients with recurrent or refractory non-Hodgkin lymphoma. Cancer 2005; 104: 781–787
   PubMed Web of Science ®Google Scholar
• Wenger C, Stern M, Herrmann R, Rochlitz C, Pless M. Rituximab plus gemcitabine: a therapeutic option for elderly or frail patients with aggressive non-Hodgkin's lymphoma?. Leuk Lymphoma 2005; 46: 71–75
   PubMed Web of Science ®Google Scholar
• Chau I, Webb A, Cunningham D, Hill M, Rao S, Ageli S, et al. An oxaliplatin-based chemotherapy in patients with relapsed or refractory intermediate and high-grade non-Hodgkin's lymphoma. Br J Haematol 2001; 115: 786–792
   PubMed Web of Science ®Google Scholar
• Morschhauser F, Depil S, Jourdan E, Wetterwald M, Bouabdallah R, Marit G, et al. Phase II study of gemcitabine-dexamethasone with or without cisplatin in relapsed or refractory mantle cell lymphoma. Ann Oncol 2007; 18: 370–375
   PubMed Web of Science ®Google Scholar
• El Gnaoui T, Dupuis J, Belhadj K, Jais J, Rahmouni A, Copie-Bergman C, et al. Rituximab, gemcitabine and oxaliplatin: an effective salvage regimen for patients with relapsed or refractory B-cell lymphoma not candidates for high-dose therapy. Ann Oncol August, 2007; 18: 1363–1368
   PubMed Web of Science ®Google Scholar
• Marce S, Molina-Arcas M, Villamor N, Casado F J, Campo E, Pastor-Anglada M, et al. Expression of human equilibrative nucleoside transporter 1 (hENT1) and its correlation with gemcitabine uptake and cytotoxicity in mantle cell lymphoma. Haematologica 2006; 91: 895–902
   PubMed Web of Science ®Google Scholar
• Schaefer-Cutillo J, Friedberg J W, Fisher R I. Novel concepts in radioimmunotherapy for non-Hodgkin's lymphoma. Oncology (Williston Park) 2007; 21: 203–212, discussion 214, 217, 221
   PubMed Web of Science ®Google Scholar
• Rummel M J, Al-Batran S E, Kim S Z, Welslau M, Hecker R, Kofahl-Krause D, et al. Bendamustine plus rituximab is effective and has a favorable toxicity profile in the treatment of mantle cell and low-grade non-Hodgkin's lymphoma. J Clin Oncol 2005; 23: 3383–3389
   PubMed Web of Science ®Google Scholar
• Forstpointner R, Dreyling M, Repp R, Hermann S, Hanel A, Metzner B, et al. The addition of rituximab to a combination of fludarabine, cyclophosphamide, mitoxantrone (FCM) significantly increases the response rate and prolongs survival as compared with FCM alone in patients with relapsed and refractory follicular and mantle cell lymphomas: results of a prospective randomized study of the German Low-Grade Lymphoma Study Group. Blood 2004; 104: 3064–3071
   PubMed Web of Science ®Google Scholar